Skip to main content
Graphical abstract for Tsukamoto et al., Targeting cap1 RNA methyltransferases as an antiviral strategy, Cell Chemical Biology (2023)

Publication

Review on new antiviral strategy now online

The review publication of Yuta Tsukamoto et al. is now available in the current issue of Cell Chemical Biology. Based on his latest Science paper, Yuta Tsukamoto now highlights the importance and potential of “Targeting cap1 RNA methyltransferases as an antiviral strategy”. He and his co-authors outline the game-changing options in the treatment of viral infections.


Publication

Tsukamoto Y, Igarashi M, Kato H.
Targeting cap1 RNA methyltransferases as an antiviral strategy.
Cell Chem Biol. 2023 Dec 5:S2451-9456(23)00426-9.
doi: 10.1016/j.chembiol.2023.11.011.
Epub ahead of print. PMID: 38091983.

Related news

News Icon

Publication

A fatal mix-up: how certain gut bacteria drive multiple sclerosis

—If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to attack its own nervous system. This mechanism can accelerate the progression of multiple sclerosis, as researchers at the University of Basel, together with colleagues in Bonn, have shown in trials with mice. However, their results also open up opportunities for treatments that make use of the microbiome. The results have now been published in the journal Gut Microbes.
View entry
News Icon

Publication

New vulnerability of asthma immune cells discovered

—Why do certain immune cells remain permanently active in allergic asthma – even in an environment that should actually damage them? A team from the University Hospital Bonn (UKB) and the University of Bonn has discovered that these cells only survive because they activate a special antioxidant protection mechanism. When this mechanism is blocked, allergic inflammation in mouse models decreases significantly. The results have now been published in the scientific journal Immunity.
View entry
The human P2X4 receptor

Publication

A starting point for the development of new pain and cancer drugs

—The human P2X4 receptor plays an important role in chronic pain, inflammation and some types of cancer. Researchers at the University of Bonn and the University Hospital Bonn (UKB) have now discovered a mechanism that can inhibit this receptor. The results were recently published in the scientific journal Nature Communications and open up a pathway for the development of new drugs. A study carried out by the University of Bonn and the University Hospital Bonn throws light on how P2X2 can be inhibited. The results have recently been published in Nature Communications.
View entry

Back to the news overview